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Fifteen patients with coronary artery spasm completed
a double-blind placebo-controlled trial comparing dil-
tiazem and nifedipine. Increasingly, higher daily doses
(diltiazem, 90 to 360 mg; nifedipine, 30 to 120 mg) were
administered to achieve optimal clinical effects. Daily
diaries and ambulatory electrocardiographic recordings
were used to assess efficacy and side effects.
Both drugs significantly decreased angina frequency
compared with that in the preceding placebo period (dil-
tiazem 1.4 ± 0.4 [mean ± SEM] to 0.4 ± 0.2 episodes
per day; nifedipine 1.4 ± 0.3 to 0.4 ± 0.1 episodes per
day; both p < 0.05). Ambulatory electrocardiographic
recordings showed fewer ST shifts than were expected
during all treatment periods (0.02/h recorded during
placebo, none during diltiazem and 0.02/h during nifed-
ipine therapy). Although Somepatients responded better
to one drug than the other, neither drug resulted in a
clearly superior clinical response.
Most patients with coronary artery spasm report a beneficial
antianginal response during therapy with diltiazem or ni-
fedipine (1-7). However, many patients are not asympto-
matic and others seem to respond better to one drug or the
other. Both diltiazem and nifedipine belong to the broad
pharmacologic class of agents referred to as calcium antag-
onists, but they have distinct chemical structures that may
have different effects on the calcium channel and use of
cellular calcium (8-10). Thus, it seems warranted to try
one agent if the other does not induce a satisfactory clinical
response. Additionally, diltiazem has been shown to poten-
tiate the pharmacologic effects of dihydropyridine calcium
antagonists such as nifedipine (8-10). Tl1us, there are data
to suggest that the combination of diltiazem and nifedipine
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Diltiazem was discontinued in one patient because of
urticaria, but the total number of side effects was higher
with nifedipine (12 of 15 patients) than with diltiazem
(5 of 15, P < 0.01). Nine patients remained symptomatic
on single drug treatment and entered open label treat-
ment with the combination of diltiazem and nifedipine.
Three patients did not tolerate the combination because
of important side effects; the other six also had side
effects, but these were relatively minor. Four patients
received no more benefit from the combination than from
a single agent; the condition of two patients improved.
Both diltiazem and nifedipine provide effective an-
tianginal therapy for coronary spasm, but diltiazem has
fewer side effects. The combination of these drugs is
associated with frequent side effects but helps some pa-
tients who remain symptomatic despite maximal toler-
ated doses of a single drug.
(J Am Coll CardioI1987;9:412-9)
may be effective even if neither works satisfactorily alone.
There are no data to suggest an interaction between diltiazem
and verapamil or nifedipine and verapamil.
We studied the anti-ischemic and antianginal effects of
diltiazem and nifedipine alone and in combination in patients
with angina at rest and coronary spasm. A double-blind,
randomized, placebo-controlled crossover design was used
to compare the safety and efficacy of single agent therapy.
An open label, unblinded design was used to assess com-
bination therapy in patients who continued having anginal
episodes with either agent alone.
Methods
Patients. Twenty-three patients were recruited over a 2
year period. Eight patients did not have a sufficient number
of anginal attacks 2:3/week) in either the first single-blind
placebo period (seven patients) or during drug "washout"
after the first double-blind treatment period (one patient)
and were excluded from evaluation of drug therapy. This
report is based on data from the remaining 15 patients. At
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Table 1. Summary of Clinical . Electrocard iograph ic and Angiographic Data in 15 Patients
Coronary Angiography
(% diameter reduction)
Age (yr) Duration of Electrocardiogram No Angina Angina LV Angiography
Patient and Sex Angina (yr) No Angina Angina Right LAD LC Right LAD LC % EF Wall Motion
62M 3 Normal ST j 0 10 60 0 10 100 58 Normal
2 67M 21 WPW WPW(ST j ) 0 0 0 50 50 80 70 Normal
3 63F 15 Normal ST ! 0 20 10 0 80 10 55 Normal
4 56M 5 Nonnal ST 1 0 0 30 100 0 30 62 Normal
5 65M 10 Nonnal ST j 10 50 10 100 50 60 12 Normal
6 12M 3 Normal Normal 90 30 90 100 30 90 44 Inf akinesia
7 56M 7 Normal ST j 0 80 0 0 100 0 70 Ant hypokinesia
8 46M II Normal Normal 0 0 20 0 90 90 65 Normal
9 62M 6 Normal ST j 0 75 90 90 90 90 78 Normal
10 56M 4 Normal Normal 0 0 10 0 50 70 65 Normal
II 45F 3 Normal ST j 40 0 0 100 0 0 63 Normal
12 35M 0.5 Normal ST j 40 0 0 100 0 0 53 Inf hypokinesia
13 74M 12 Normal Normal 50 50 50 50 80 80 64 Ant hypokinesia
14 62F 20 Normal ST j 0 40 0 0 40 100 78 Normal
15 53M 10 Nonnal Normal () 0 0 0 60 50 65 Normal
Ant = anterior; EF = ejection fraction; F = female; Inf = inferior; LAD = anterior descending coronary artery; LC = left circumflex coronary
artery; LV = left ventricular; M = male; Right = right coronary artery; ST ! = ST segment depression; ST j = ST segment elevation: WPW =
Wolff-Parkinson-White abnormality,
rest or during normal daily activity, all had ischemic-type
chest pain that was relieved by sublingual nitroglycerin .
None had other forms of heart disease or heart failure.
Pertinent clinical findings are summarized in Table I. Coro-
nary angiography during spontaneous or ergono vine-in-
duced angina documented coronary spasm in all 15 patients.
Fourteen of the 15 patients had been previously exposed
to calcium antagonists or long-acting nitrates, or both (Table
2). To avoid bias, we entered no patient who reported pre-
vious important adverse effects or a poor clinical response
to either nifedipine or diltiazem. This study was approved
Table 2. Summary of Prior Ant ianginal Drug Exposure
by appropriate institutional review committees (November
18, 1982) and each patient gave informed written consent.
Study design. No patient had taken antianginal medi-
cation other than sublingual nitroglycerin (0 .4 mg) for at
least 72 hours before the study . Because of continued fre-
quent angina after discontinuing calcium antagoni st therapy,
two patients (Cases 13 and 15) continued to receive long
acting nitrates in a constant dose throughout the study. The
study protocol comprised five phases (Fig. I).
Phase J: first single-blind placebo phase. During this 2
week period only patients with at least three attacks per
Long-Acting
Case Diltiazem Nifedipine Nicardipine Perhexiline Verapamil Beta-Blocker Nitrates
I + + +
2 + + + +
3 + + +
4 + + + + + +
5 + + + + + + +
6 + + +
7 + + + + + + +
8 + + +
9 + + + + +
10 + +
II + +
12 +
13 + + +
14 +
15 + + + + +
+ = Prior exposure; - = no prior exposure.
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Figure1. Outline of study design. The
study wasorganized into five phases-
two placebo periods (Single Blind),
two treatment periods (Double Blind)
and one combination treatmentperiod
(Open-Label). The numberof patients
who completed each period is shown
at the top.
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week of angina at rest were eligible to continue. If after at
least six attacks the frequency and severity of angina were
considered by two investigators to be unacceptable, the pa-
tient was entered early into double-blind randomized ther-
apy. Patients in phase I took two capsules (placebo) three
times daily.
Phase 2: first double-blind treatment phase. A double
dummy technique was used so that a patient received cap-
sules containing either diltiazem (30 mg) or nifedipine (10
mg) orally. These capsules were prepared in prepackaged
coded bottles and were supplied by Marion Laboratories.
Each patient was assigned a coded set for use during the
two double-blind treatment phases. Treatment was initiated
with one capsule three times daily. Every 3 to 7 days over
the first 2 weeks of this period the dose was increased by
one additional capsule until the patient was asymptomatic
or the maximally tolerated dose was found or until the pa-
tient received four capsules three times daily. This was then
considered the optimal dose and was continued for another
2 weeks. Thus, patients could receive 90 to 360 mg of
diltiazem or 30 to 120 mg of nifedipine per day.
Phase 3: second single-blind placebo phase. The med-
ication administered during the first double-blind phase was
discontinued abruptly. Patients then entered a "washout"
period and again received two capsules (placebo) three times
daily. The washout was employed because of prior expe-
rience testing efficacy of calcium antagonists in patients with
coronary spasm whose symptoms frequently remitted during
repeat placebo periods (l ,3,5). This washout lasted between
I day and 4 weeks and was continued until angina recurred.
If angina did not recur at a minimal frequency of approx-
imately three attacks a week, the patient was eliminated
from the study. When anginal attacks resumed at a level
similar to that during the first placebo period, the second
placebo period was begun and was continued for another 2
weeks. When the frequency of angina warranted increased
medication, placebo was increased stepwise to two, three
or four capsules three times daily, as it was during the first
double-blind treatment phase (phase 2). During this period,
as in the first placebo period (phase I), similar early ad-
vancement to the next double-blind treatment phase was
possible.
Phase 4: second double-blind treatment phase. The same
coded set of bottles was used for all patients so that they
received either diltiazem or nifedipine, depending on which
active drug was given during the first treatment. Drug ti-
tration to optimal dosage was performed in a manner iden-
tical to that in the first treatment phase.
Phase 5: open label combination treatment phase. Pa-
tients who continued to have angina during treatment with
the optimal dose during both double-blind treatment periods
and who had no important side effects from single agent
treatment were invited to participate in the combination
treatment. The data on both prior treatments were disclosed
and the patient continued to receive the optimal dose of the
drug the investigators and the patient preferred. The other
drug was added starting with one capsule (30 mg diltiazem
or 10 mg nifedipine) three times daily. The dose of the
second drug was increased by one capsule every 3 to 7 days
over the first 2 weeks until an optimal response occurred.
Optimal dose was defined as either the dose that rendered
the patient asymptomatic or the highest tolerated dose. The
optimal dose was continued for an additional 2 weeks.
Assessment of patient responses. On entering the study,
the patients underwent a complete history and physical ex-
amination and electrocardiogram. They were examined at
least every 2 weeks and after each placebo and treatment
period. Symptom responses were assessed from a daily di-
ary. Adverse effects were assessed by questioning the pa-
tient at each visit. Patient compliance was monitored by
counts of unused capsules returned at each visit. Ambulatory
electrocardiographic responses were evaluated by visual in-
spection from calibrated two channel, 24 hour cassette re-
cordings at the end of each placebo and treatment period.
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Two bipolar leads corresponding to standard electrocardio-
graphic leads VI and Vs were used. The recorder used for
each patient was a Holter model 7200 (Instruments for Car-
diac Research, Inc). New tape was placed in each recorder
and calibration and position tests were recorded. All patients
kept an additional diary noting time of symptoms and ac-
tivities during recording periods and they were instructed
to push the event marker button during attacks of angina.
Electrocardiograms recorded on the ambulatory patients were
analyzed without knowledge of their clinical response or
treatment group. An ischemic episode was defined as an ST
segment elevation or depression of at least I mm from
baseline for more than I minute.
Data analysis. On completion of the blinded phases,
the coded bottles were identified. Clinical responses were
evaluated by analyzing frequency of angina, consumption
of nitroglycerin and adverse effects. For each patient, the
mean daily number of anginal attacks and nitroglycerin tab-
lets used during both 2 week placebo periods and the final
2 weeks of each drug treatment period was calculated. Val-
ues are expressed as mean ± SEM.
During the placebo and the 2 week optimal dose phases
of drug treatment, drug efficacy was assessed by comparing
frequency of angina and nitroglycerin consumption as well
as the number of ischemic episodes recorded by ambulatory
electrocardiograph. The number of patients experiencing an
adverse effect and the adverse effects themselves were tab-
ulated for both placebo and drug treatment periods. Before
breaking the code, we determined adverse effects that were
related to drug treatment by comparing them during placebo
and treatment phases. Because a patient could report more
than one adverse effect, the type and number of specific
advetse effects were also tabulated.
Statistical analysis. A paired Student's t test was used
to evaluate the statistical significance of differences in an-
gina frequency and nitroglycerin consumption. Three com-
parisons were made: I) between the two placebo periods;
2) between the two treatment periods; and 3) between each
treatment period and its preceding placebo period. The sta-
tistical significance of differences in frequency of adverse
effects reported during double-blind diltiazem and nifedi-
pine periods was determined by the Fisher's exact test. A
probability value of 0.05 or less was considered significant.
Results
Adverse effects and daily diary findings with respect to
angina frequency and nitroglycerin consumption are sum-
marized in Tables 3 and 4, respectively.
Adverse effects (Table 3). No changes in heart rate,
blood pressure or 12 lead electrocardiogram were found.
Adverse effects on the optimal dose were reported by 5 of
15patients during diltiazem therapy, 12of IS patients during
nifedipine therapy (p < 0.05 compared with diltiazem) and
9 of 9 patients during combination therapy with diltiazem
and nifedipine (p < 0.05 compared with diltiazem, p =
NS compared with nifedipine). All five patients reporting
adverse effects with diltiazem also reported adverse expe-
riences with nifedipine. The frequency of specific adverse
effects was similar during treatment with diltiazem or ni-
fedipine. During dose titration of the first double-blind drug
treatment period, urticaria developed in Patient IS. The drug
was discontinued and the rash began clearing within 48
hours. During combination therapy, three patients (Cases
3, 7 and 12) who tolerated diltiazem and nifedipine alone
reported dizziness, which necessitated early termination of
treatment before meaningful data on clinical efficacy were
obtained.
Optimal doses (Fig. 2). The optimal dose of diltiazem
averaged 257 mg (range 90 to 360) and that of nifedipine
averaged 82 mg (range 30 to 120). During combination
treatment, the diltiazem dose averaged 206 mg (range 90
Table 3. Adverse Effects Related to Drug Therapy in 15 Patients
o
2
2
I
3*
I
2
2
2
15
9/9
Diltiazem Nifedipine
No. of patients with adverse 5115 12/15
experiences/total
Specific adverse effects (no.) 6 13
Type
Rash 1* 0
Edema I 3
Headache I I
Flushing 0 1
Dizziness 0 I
Dry eyes I I
Impotence 2 2
Tremor 0 I
Gastrointestinal (nausea. 0 3
indigestion. constipation)
Diltiazem and
Nifedipine
*Adverse effect that necessitated discontinuation of therapy.
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Table 4. Summary of Patient Diary Findings
Placebo I Placebo II Diltiazem Nifedipine
Case Angina NTG Angina NTG Angina NTG Order Angina NTG Order
I 1.07 0.84 4.20 4.80 0.00 0.00 2 0.14 0.00 I
2 0.80 1.00 1.30 lAO 0.14 0.28 I 0.00 0.00 2
3 0.50 0.60 0.30 0.00 0.05 0.10 I 0.05 0.05 2
4 4.00 5.00 1.70 2.30 0.64 0.80 2 0.70 0.90 I
5 DAD DAD 0.60 DAD 0.20 0.12 I 0.20 0.20 2
6 0.60 0.70 0.90 1.10 0.20 0.20 I 0.00 0.00 2
7 1.00 0.90 DAD DAD DAD DAD 2 0.20 0.20 1
8 1.80 1.90 1.00 2.00 0.15 0.00 2 1.00 0.60 I
9 0.50 0.60 0040 DAD 0.10 0.10 I 0.00 0.00 2
10 0.60 0.80 0040 0.30 0.50 0.30 I 0.12 0.25 2
11 2.00 0.00 0.30 0.05 0.10 0.00 I 0.03 0.00 2
12 1.60 0.70 2.00 1.00 1.60 0.30 I 0.30 0040 2
13 1.70 1.80 0.30 0.00 0.05 0.05 2 0.30 0040 1
14 0.80 0040 0.30 0.16 0.80 0.20 2 0.42 0.14 I
15 4.00 13.00 4040 9.00 1.90 5.10 2 1.50 4.00 I
Angina is reported as episodes per day. NTG = nitroglycerin tablets consumed per day; order = the order in which drug was received during the
first (I) or second (2) double-blind treatment period.
to 360 mg) and the nifedipine dose averaged 61 mg (range
30 to 90),
Symptom responses (Table 4). Comparison of the two
placebo periods showed a similar frequency of anginal at-
tacks and nitroglycerin consumption (Fig. 3). Despite design
of the protocol to avoid spontaneous remission of angina,
the frequency of angina declined by at least 50% in five
patients (Cases 4,7, II. 13 and 14) during the second
placebo period compared with the first. However, in Patient
1, angina frequency increased by at least 50% during the
second placebo period.
Compared with the preceding placebo period, the optimal
dose of diltiazem and of nifedipine decreased the frequency
of angina and nitroglycerin consumption (Fig. 4 and 5).
Diltiazem decreased angina frequency by an average of 71%
and nitroglycerin consumption by 65% (both P < 0.05).
During diltiazem therapy (14 patients) 1 patient (7%) was
asymptomatic, II patients (79%) had at least a 50% reduc-
tion in angina and 2 (14%) had no important change. Ni-
fedipine decreased the frequency of angina by an average
of 74% and decreased nitroglycerin consumption by 75%
Figure 2. Optimal daily dose of diltiazem and nifedipine.
(both P < 0.05). During nifedipine therapy (15 patients),
3 patients (20%) were asymptomatic, 9 (60%) had at least
a 50% reduction in angina, 2 (13%) had a reduction of
between 25 and 50% and 1 (7%) had no important changes.
No significant group differences were observed between
clinical responses with diltiazem and nifedipine. During
combination therapy with the two drugs, all six patients who
tolerated the regimen reported a reduction in angina fre-
quency of at least 50% (average 0.36 episode per day),
compared with that during both preceding placebo periods
(average of 1.75 episodes per day both placebo periods).
However, in only two of these six was there a 50% or greater
reduction in angina as compared with the reduction during
treatment with either diltiazem or nifedipine alone.
No significant difference in disease activity or clinical
response to either drug was found when comparing patients
with and without severe coronary artery disease. The need
to proceed to combination therapy was equally common
regardless of the patients' coronary anatomy, and the par-
Figure 3. Comparison of angina frequency (left) and nitroglycerin
consumption (right) during the first and second placebo periods.
Both placebo periods were similar.
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Figure 4. Summary of angina frequency (left) and nitroglycerin
consumption (right) during the two treatment periods compared
with the preceding placebo period, Both diltiazem and nifedipine
decreased angina frequency and nitroglycerin consumption.
Discussion
Effectiveness of calcium antagonists in patients with
coronary artery spasm. This study confirms that diltiazem
and nifedipine are effective antianginal agents for therapy
of rest angina and coronary artery spasm. The clinical benefit
of both calcium antagonists was excellent, with some pa-
tients seeming to have a better response to one or the other.
Furthermore, in patients who continued to have symptoms
despite treatment with one drug, the combination of dilti-
azem and nifedipine often produced additional clinical ben-
efit.
This study extends the findings of prior investigations
(1-7) that demonstrated that diltiazem and nifedipine clin-
ically benefited patients with rest angina and coronary spasm
regardless of whether they had severe coronary disease and
regardless of which coronary artery was affected by spasm.
Our study differs in that the same patients were exposed to
both calcium antagonists; therefore. our study allows some
direct comparisons between the drugs. Both diltiazem and
nifedipine considerably reduced the frequency of attacks of
angina and the number of nitroglycerin tablets taken; how-
ever. only a few patients were totally asymptomatic. Thus,
responses to therapy were similar to those in other controlled
trials of calcium antagonists in patients with coronary spasm
(1-6.11,12). Nifedipine reduced by at least 50% the number
of anginal episodes in slightly more patients than did dil-
tiazem (p = NS); however, diltiazem seemed to prevent
electrocardiographically documented ischemic ST shifts more
often than did nifedipine. Some patients clearly benefited
more from one drug than the other, but this was not pre-
dictable. Patients with an unsatisfactory response to one
the two patients showing such abnormalities with placebo)
and none had complex ventricular arrhythmias or inappro-
priate sinus tachycardia. During 327 hours of recording
during nifedipine treatment, four ischemic episodes oc-
curred and two (50%) were associated with symptoms. Two
patients had conduction disturbances (the same two showing
such abnormalities with placebo), three patients had inap-
propriate sinus tachycardia and none had complex ventric-
ular arrhythmias. During 263.5 hours of recording during
combination treatment with diltiazem and nifedipine, only
one ischemic episode was registered; this was not associated
with symptoms. One patient had inappropriate sinus tachy-
cardia, and none had conduction disturbances or complex
ventricular arrhythmias. In general, diltiazem (no ST shifts)
but not nifedipine (0.018 ST shift/h of recording) seemed
to decrease ambulatory electrocardiographic monitoring evi-
dence of ischemia compared with that seen with placebo
(0.017 ST shift/h of recording); however, because the num-
ber of recorded ischemic episodes was small, no statistical
testing was performed.
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Figure 5. Summary of clinical efficacy of diltiazem and nifedipine
alone and in combination compared with placebo. The percent of
patients with a particular range of responses (no change or increase
in angina frequency, greater than 25 but less than 50% reduction
or greater than 50% reduction or asymptomatic) is shown on the
vertical axis. Most patients had reduction in angina frequency of
at least 50% with single agent therapy. All patients who tolerated
the combination of diltiazem and nifedipine had a reduction in
angina frequency of at least 50%.
ticular coronary artery that was affected with spasm was not
predictive of disease activity or clinical response.
Ambulatory electrocardiographic monitoring. Re-
cordings technically adequate for ST segment analysis were
available for all patients. During 597 hours of recordings
during the two placebo periods, 10 ischemic episodes oc-
curred; only 4 (40%) were associated with angina, Two
patients had evidence of important conduction disturbance
(first degree atrioventricular block in one and second degree
sinoatrial block in the other); none had complex ventricular
extrasystoles and one had what we termed "inappropriate
sinus tachycardia" (that is, heart rate of more than 110
beats/min at rest or during sleep). During 332 hours of
recording during diltiazem treatment, no ischemic episodes
occurred. One patient had a conduction disturbance (one of
418 PRIDA ET AL.
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calcium antagonist should definitely have a clinical trial with
another.
Adverse effects related to diltiazem and nifedipine.
Adverse experiences were more common during treatment
with nifedipine than with diltiazem. In general, these were
mild and did not necessitate discontinuing therapy. Our
previous experience with diltiazem (1,2) had also shown
very few adverse effects, but the maximal total daily dose
was only 240 mg/day. The present study showed that even
with diltiazem doses as high as 360 mg/day, adverse effects
were low.
Combined diltiazem and nifedipine. Combination
therapy with both calcium antagonists benefited some pa-
tients (22%) who responded unsatisfactorily to either drug
alone. However, adverse effects occurred in all patients and
in three of nine patients necessitated discontinuation of the
combination treatment soon after it began. Other patients
(44%) had no more benefit from combination therapy than
from single drug therapy. The reason that adverse effects
were so common is unclear, but it may have been that
nifedipine's vasodilatory effects were potentiated by dilti-
azem (8-10). Perhaps if lower doses of drugs had been used
during the combination phase, adverse effects would have
been less frequent. For patients with rest angina and coro-
nary spasm who have had an unsatisfactory clinical response
to therapy with only one calcium antagonist, other possible
combinations of treatment include a calcium antagonist plus
long-acting nitrates. Because of frequent angina during
withdrawal of prior therapy, two of our patients received
long-acting nitrates throughout the study. One of these pa-
tients (Case 15) showed the greatest improvement with "tri-
ple therapy. " No controlled trial has compared single agent
therapy with the efficacy of the combination of a calcium
antagonist and a long-acting nitrate. No pharmacologic in-
teraction would be expected with other combinations of the
available calcium antagonists (8-10). However, combining
nifedipine and verapamil makes physiologic sense, but in
our opinion diltiazem and verapamil may not be a good
combination because of similarity of physiologic effects.
Description of patients and trial design. All these pa-
tients had major coronary angiographic changes during either
spontaneous or ergonovine-induced angina. Nine had re-
versible ST segment elevation and one had reversible ST
segment depression during episodes of rest angina. Five
patients did not have electrocardiographic changes diag-
nostic of transient myocardial ischemia during rest angina.
Thus, although all patients had coronary artery spasm by
angiographic criteria, only nine had the group of clinical
features to make the diagnosis of Prinzmetal' s variant angina
(for example, rest angina, reversible ST segment elevation
and no evidence of myocardial necrosis). This emphasizes
that in addition to patients with Prinzmetal's variant angina,
other patients with rest anginal syndromes often have coro-
nary artery spasm. The number of patients in this trial was
too small for extensive subgroup analyses. However, the
response to either diltiazem or nifedipine alone or the need
to try combination therapy was not obviously predicted by
the extent and severity of accompanying coronary artery
disease, the coronary artery involved by spasm or the clinical
presentation (presence or absence of variant angina). These
results are similar to our findings in other drug trials
(1,2,4,11,13) in patients with coronary spasm; coronary
anatomy and clinical presentation did not predict clinical
responses. Our patients represent a select group because
most had prior exposure to multiple antianginal medications.
To avoid potential bias, we did not enroll patients in whom
open label therapy with only one of the two study medi-
cations had previously failed.
The design of this study was unique in that we allowed
for a washout period after the first double-blind drug treat-
ment and waited for angina to recur at what seemed a similar
frequency before beginning the second single-blind placebo
phase. We did this because of the high frequency of either
drug-induced or spontaneous remissions that many inves-
tigators (1,3,4,6,11) have found in patients with coronary
spasm. Overall, the frequency of anginal attacks was similar
during the first and second placebo periods. Although fre-
quency of angina varied between placebo periods because
some patients had a slight increase or decrease, only one
patient met the criteria proposed by Rosenthal et al. (3) for
spontaneous remission. This patient was eliminated from
the study after the first drug treatment period and his data
were not included.
Ambulatory electrocardiographic monitoring to aid
assessment of drug efficacy. In addition to clinical re-
sponse of frequency of anginal attacks and nitroglycerin
consumption, ambulatory electrocardiographic monitoring
can provide objective noninvasive evidence of frequency of
transient myocardial ischemia and effects of therapy
(11,12,14). Ambulatory electrocardiographic monitoring can
also assess average heart rate throughout the day and fre-
quency of rhythm disturbances. During all periods we re-
corded fewer ischemic electrocardiographic episodes than
were expected. This may have been related to the recording
system because two bipolar leads that were similar to stan-
dard leads VIand V5 were used in all patients. ST shifts
shown only in leads reflecting the inferior region may have
been missed. Because of the few ischemic episodes re-
corded, caution seems appropriate in assessing changes be-
tween periods. Compared with ischemic episodes during the
placebo phases, there seemed to be fewer episodes during
treatment with diltiazem or the combination of diltiazem
and nifedipine. Nifedipine treatment apparently did not de-
crease the frequency of ischemic episodes, but this may
have been due to the few episodes recorded, because ni-
fedipine was very efficacious clinically. Ambulatory mon-
itoring also showed the clinical safety of either drug alone
or of both in combination because neither was arrhythmo-
JACCVol. 9, No.2
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genic or induced heart block. Sinus tachycardia occasionally
occurred when the patient was at rest or even sleeping during
nifedipine therapy but not during diltiazem treatment.
Conclusions. Both diltiazem and nifedipine were safe
and efficacious for preventing rest angina due to coronary
spasm, Some patients responded better to one drug than to
the other, but this was not predictable, Patients who remain
symptomatic in spite of maximal doses of a single drug may
receive some benefit from combination therapy but many
may have side effects.
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